Discover
ENGN
enGene Therapeutics Inc.
1.76
2 x 1.29
2 x 2.22
bid
ask
+
0.03
1.73%
2 @ 04:00 PM
1.76 +0.00 (0.00%)
| Ytd | -80.51% | |
| 1y | -51.38% |
1.73
day range
1.78
1.40
52 week range
12.25
| Open | 1.74 | Prev Close | 1.73 | Low | 1.73 | High | 1.78 | Mkt Cap | 117.90M |
| Vol | 605.23K | Avg Vol | 1.74M | EPS | -2.18 | P/E | N/A | Forward P/E | -3.53 |
| Beta | -0.76 | Short Ratio | 11.39 | Inst. Own | 83.23% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 09-14 | 50-d Avg | 3.15 | 200-d Avg | 6.95 | 1yr Est | 27.00 |
ENGN News
benzinga.com
This Intuit Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday
Wall Street analysts updated ratings for CURB, INTU, ENGN. See their outlooks and targets at Benzing
benzinga.com
Morgan Stanley Downgrades enGene Therapeutics to Underweight
Morgan Stanley analyst Judah Frommer downgrades enGene Therapeutics (NASDAQ:ENGN) from Equal-Weig
benzinga.com
W.P. Carey To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday
Top analysts changed ratings on top names, including Sunrun, enGene Therapeutics, Camp4 Therapeutics
benzinga.com
HC Wainwright & Co. Maintains Buy on enGene Therapeutics, Lowers Price Target to $4
HC Wainwright & Co. analyst Andres Y. Maldonado maintains enGene Therapeutics (NASDAQ:ENGN) w
benzinga.com
EnGene Therapeutics Implements Workforce Reduction Of About 50% In June 2026; CFO Ryan Daws To Depar
Recent Corporate UpdatesReduction in Force and Executive Departures: In June 2026, enGene implemente
benzinga.com
enGene Holdings Q2 EPS $(0.43) Beats $(0.47) Estimate
enGene Holdings (NASDAQ:ENGN) reported quarterly losses of $(0.43) per share which beat the analyst